Skip to content

Integrating malaria vaccine with seasonal malaria chemoprevention in West Africa (IMVACS)

Integrating malaria vaccine with seasonal malaria chemoprevention in West Africa

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
PACTR
Registry ID
PACTR202502765006598
Enrollment
40000
Registered
2025-02-05
Start date
2025-04-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria Paediatrics

Interventions

Sponsors

Epicentre
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Control arms (1) Children aged 5-36 months in Burkina Faso and Mali at the time of first study vaccination; (2) Resident in the catchment area of a health centre assigned to the control arm; (3) Willingness to comply with the study procedures; (4) Written informed consent from Parent/Guardian. Intervention arms (1) Children aged 3-59 months at the time of first study vaccination; (2) Resident in the catchment area of a health centre assigned to the intervention arm; (3) Willingness to comply with the study procedures; (4) Written informed consent from Parent/Guardian

Exclusion criteria

Exclusion criteria: (1) History of allergic disease or reactions likely to be exacerbated by any component of the Vaccines; (2) Any history of anaphylaxis in relation to vaccination; (3) Known chronic illness; (4) Any other significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial; (5) History of vaccination with another malaria vaccine.

Design outcomes

Primary

MeasureTime frame
Malaria Incidence on 5-36 months at 12 months

Secondary

MeasureTime frame
Malaria incidence among children aged 5-36 months over 24 and 36 months;Malaria incidence among children aged 3-59 months over 24 and 36 months;Malaria prevalence at peak transmission;Vaccine coverage;Occurrence of adverse events (AEs) and serious adverse events (SAEs) following R21/Matrix-M vaccination;Acceptability;Feasibility;Contextual and behavioural factors impeding or facilitating R21/Matrix-M vaccine uptake; Factors that enhance and/or constrain the successful completion of four doses of R21;Cost-effectiveness

Countries

Burkina Faso, Mali

Contacts

Public ContactSoazic Gardais

Project manager

soazic.gardais@epicentre.msf.org+33140215555

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026